China Isotope & Radiation Corporation (1763.HK) Comparison with companies in other sectors?

China Isotope & Radiation Corporation has a share price of 333.05M. You can analyze China Isotope & Radiation Corporation (1763.HK) competitors across different market sectors through stock heatmaps.

What are 1763.HK's NET and operating margins?

China Isotope & Radiation Corporation (1763.HK) operating margin is around 0.14, and net profit margin is approximately 0.05 as of the latest reports.

In what way does 1763.HK's earnings per share (EPS) trend reflect its financial momentum?

China Isotope & Radiation Corporation (1763.HK) EPS is 1.39 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for China Isotope & Radiation Corporation is 12.88, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for China Isotope & Radiation Corporation?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for China Isotope & Radiation Corporation like P/E which is 12.89, P/B which is 1.05, and PEG which is 5.82. Compare them with sector averages to evaluate if the stock is priced fairly.

China Isotope & Radiation Corporation

1763.HK•HKSE

Healthcare

Medical - Devices

HK$18.96

HK$0.75(4.12%)

China Isotope & Radiation Corporation (1763.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$1.39

P/E Ratio

12.88

ROE

0.08%

Net Margin

0.05%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$5.96B

Shares OutstandingTotal number of shares issued

$333.05M

Book Value/ShareNet worth per share

$24.21

Revenue/ShareAnnual revenue per share

$23.68

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.39

Net MarginNet income as percentage of revenue

5.37%

Operating MarginOperating income as percentage of revenue

14.34%

ROEReturn on shareholders' equity

8.34%

ROAReturn on total assets

2.75%

ROCEReturn on capital employed

11.15%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-1.76

Cash/ShareCash and equivalents per share

$9.13

FCF YieldFree cash flow as percentage of market cap

-10.31%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.38

Dividend YieldAnnual dividend as percentage of stock price

2.33%

Financial Ratios Analysis data is not available for 1763.HKFinancial Ratios Analysis details for 1763.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 1763.HKSector Benchmarking details for 1763.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for China Isotope & Radiation Corporation Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of China Isotope & Radiation Corporation. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account China Isotope & Radiation Corporation's unique business strengths and challenges.

Key Financial Metrics for China Isotope & Radiation Corporation

For China Isotope & Radiation Corporation, essential financial indicators include EPS 1.39, PE 12.88, and ROE 0.08. These key ratios reveal insights into China Isotope & Radiation Corporation's profitability, valuation, and operational health. Understanding these metrics enables you to compare China Isotope & Radiation Corporation with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of China Isotope & Radiation Corporation

Metrics like Net Margin 5.37% and ROA 2.75% shed light on how well China Isotope & Radiation Corporation is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether China Isotope & Radiation Corporation can sustain its operations and continue growing in the future.

Valuation and Market Position of China Isotope & Radiation Corporation

Using ratios such as P/B Ratio 1.05 and PEG Ratio 5.82, investors can assess whether China Isotope & Radiation Corporation is appropriately valued based on its financials and growth potential. These figures, combined with China Isotope & Radiation Corporation's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for China Isotope & Radiation Corporation

Financial health indicators, such as Debt/Equity Ratio 0.51 and Cash Flow $-1.76, provide a snapshot of China Isotope & Radiation Corporation's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like China Isotope & Radiation Corporation, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for China Isotope & Radiation Corporation

Investing in China Isotope & Radiation Corporation based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at China Isotope & Radiation Corporation focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;